Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INCCOLL · Entity 5169 | Director | May 14, 2026 | May 18, 2026 |
| Karyopharm Therapeutics Inc.KPTI · Entity 781 | Director | May 21, 2026 | May 26, 2026 |
| Protara Therapeutics, Inc.PRTO · Entity 6203 | Director | June 08, 2018 | June 11, 2018 |
| TETRAPHASE PHARMACEUTICALS INCTTPH · Entity 147285 | Director | June 10, 2019 | June 11, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COLLEGIUM PHARMACEUTICAL, INC
Report date May 14, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 71,000 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 8,741 · Balance 71,000 F1: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the earlier of May 14, 2027, or the date of the Issuer's 2027 Annual Meeting of Shareholders, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the earlier of May 14, 2027, or the date of the Issuer's 2027 Annual Meeting of Shareholders, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.
Karyopharm Therapeutics Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,517 |
Reported balance
After 2026-05-21 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 15,508 · Balance 18,517 F1: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on May 21, 2027; however, delivery of the shares is deferred until the earlier of (a) the date of the director's separation from service to Karyopharm Therapeutics Inc. and (b) a change-in-control event. F2: Amounts reported in this Form 4 reflect the one-for fifteen reverse stock split effected by Karyopharm Therapeutics Inc. on February 25, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on May 21, 2027; however, delivery of the shares is deferred until the earlier of (a) the date of the director's separation from service to Karyopharm Therapeutics Inc. and (b) a change-in-control event.
F2: Amounts reported in this Form 4 reflect the one-for fifteen reverse stock split effected by Karyopharm Therapeutics Inc. on February 25, 2025.
Protara Therapeutics, Inc.
Report date June 08, 2018 · Filed June 11, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.50 · Expires 2028-06-07 | Direct | 12,700 |
Reported balance
After 2018-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-08 · Grant · Acquired 12,700 · Balance 12,700 F1: The options were granted on June 8, 2018 and the shares underlying this option will vest 100% at the earlier of (i) June 8, 2019 and (ii) the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on June 8, 2018 and the shares underlying this option will vest 100% at the earlier of (i) June 8, 2019 and (ii) the Issuer's next annual meeting of stockholders.
TETRAPHASE PHARMACEUTICALS INC
Report date June 10, 2019 · Filed June 11, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.77 · Expires 2029-06-09 | Direct | 16,500 |
Reported balance
After 2019-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-10 · Grant · Acquired 16,500 · Balance 16,500 F1: Vests in equal quarterly installments over a one-year period measured from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Vests in equal quarterly installments over a one-year period measured from the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2026 Filed May 26, 2026 20:12 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantCommon Stock | 15,508 | $0.00 | $0.00 |
DisclosureSEC source: 0001254705-26-000008 · ownership.xml · nonDerivative · entry 1 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,517 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on May 21, 2027; however, delivery of the shares is deferred until the earlier of (a) the date of the director's separation from service to Karyopharm Therapeutics Inc. and (b) a change-in-control event. F2 · balance_after: Amounts reported in this Form 4 reflect the one-for fifteen reverse stock split effected by Karyopharm Therapeutics Inc. on February 25, 2025. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:15 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 8,741 | $0.00 | $0.00 |
DisclosureSEC source: 0001254705-26-000004 · form4-05182026_040510.xml · nonDerivative · entry 1 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,000 F1 · kind: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the earlier of May 14, 2027, or the date of the Issuer's 2027 Annual Meeting of Shareholders, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock. Read SEC document |
| May 11, 2026 Filed May 13, 2026 20:05 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 8,700 | $0.00 Strike: $16.49 | $0.00 |
DisclosureSEC source: 0001254705-26-000002 · form4-05132026_040501.xml · derivative · entry 3 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,700 shares Expires 2026-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 11, 2026 Filed May 13, 2026 20:05 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 8,700 | $37.18 | $323,491.23 |
DisclosureSEC source: 0001254705-26-000002 · form4-05132026_040501.xml · nonDerivative · entry 2 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,259 F1 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.18 to $37.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 11, 2026 Filed May 13, 2026 20:05 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 8,700 | $16.49 | $143,463.00 |
DisclosureSEC source: 0001254705-26-000002 · form4-05132026_040501.xml · nonDerivative · entry 1 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,959 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2025 Filed May 29, 2025 20:05 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 4,600 | $0.00 Strike: $4.48 | $0.00 |
DisclosureSEC source: 0000950170-25-078937 · ownership.xml · derivative · entry 1 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,600 Underlying: Common Stock · 4,600 shares Expires 2035-05-27 F1 · derivative.exercise_price: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. F1 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. F2 · derivative.exercise_date: This option vests as to 100% of the underlying shares on May 28, 2026. F1 · derivative.underlying_shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. F1 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. Read SEC document |
| May 15, 2025 Filed May 19, 2025 21:42 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 9,791 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-009808 · form4.xml · nonDerivative · entry 1 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,259 F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the earlier of May 15, 2026, or the date of the Issuer's 2026 Annual Meeting of Shareholders, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock. Read SEC document |
| May 29, 2024 Filed May 30, 2024 21:19 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 69,000 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0000950170-24-066771 · ownership.xml · derivative · entry 1 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,000 Underlying: Common Stock · 69,000 shares Expires 2034-05-28 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on May 29, 2025. Read SEC document |
| May 16, 2024 Filed May 16, 2024 23:20 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 7,693 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-010536 · form4.xml · nonDerivative · entry 3 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,468 F2 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on May 16, 2025, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock. Read SEC document |
| May 14, 2024 Filed May 16, 2024 23:20 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 28,985 | $0.00 Strike: $5.73 | $0.00 |
DisclosureSEC source: 0001062993-24-010536 · form4.xml · derivative · entry 4 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,985 shares Expires 2025-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 14, 2024 Filed May 16, 2024 23:20 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 28,985 | $32.30 | $936,311.15 |
DisclosureSEC source: 0001062993-24-010536 · form4.xml · nonDerivative · entry 2 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,775 F1 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.00 to $32.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 14, 2024 Filed May 16, 2024 23:20 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 28,985 | $5.73 | $166,084.05 |
DisclosureSEC source: 0001062993-24-010536 · form4.xml · nonDerivative · entry 1 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,760 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 12, 2023 Filed Sep 12, 2023 20:07 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | PurchaseCommon Stock | 41,140 | $1.22 | $49,985.10 |
DisclosureSEC source: 0000950170-23-047712 · ownership.xml · nonDerivative · entry 1 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,140 F1 · price: Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $1.1935 to $1.24, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.. Read SEC document |
| May 24, 2023 Filed May 25, 2023 20:05 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 34,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001209191-23-032138 · doc4.xml · derivative · entry 1 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2033-05-23 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on May 24, 2024. Read SEC document |
| May 18, 2023 Filed May 19, 2023 20:37 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 9,792 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-011813 · form4.xml · nonDerivative · entry 1 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,775 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 18, 2024, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock. Read SEC document |
| May 19, 2022 Filed May 20, 2022 20:03 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 23,900 | $0.00 Strike: $5.65 | $0.00 |
DisclosureSEC source: 0001209191-22-030956 · doc4.xml · derivative · entry 1 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,900 Underlying: Common Stock · 23,900 shares Expires 2032-05-18 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on the earlier of May 19, 2023 or the next annual meeting of stockholders of Karyopharm Therapeutics Inc. Read SEC document |
| May 19, 2022 Filed May 23, 2022 20:43 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 14,035 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-013300 · form4.xml · nonDerivative · entry 1 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,983 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 19, 2023, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock. Read SEC document |
| May 21, 2021 Filed May 21, 2021 21:31 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 23,900 | $0.00 Strike: $9.42 | $0.00 |
DisclosureSEC source: 0001209191-21-035024 · doc4.xml · derivative · entry 1 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,900 Underlying: Common Stock · 23,900 shares Expires 2031-05-20 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on the earlier of May 21, 2022 or the next annual meeting of stockholders of Karyopharm Therapeutics Inc. (the "Issuer"), provided that the reporting person continues to serve as a director of the Issuer through such date. Read SEC document |
| May 20, 2021 Filed May 24, 2021 21:14 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 9,941 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-21-000453 · edgar.xml · nonDerivative · entry 1 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,948 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 20, 2022, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock. Read SEC document |
| May 06, 2021 Filed May 10, 2021 23:57 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | PurchaseCommon Stock | 4,000 | $7.82 | $31,280.00 |
DisclosureSEC source: 0001209191-21-031437 · doc4.xml · nonDerivative · entry 1 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Read SEC document |
| May 21, 2020 Filed May 26, 2020 20:18 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 16,400 | $0.00 Strike: $19.11 | $0.00 |
DisclosureSEC source: 0001209191-20-032001 · doc4.xml · derivative · entry 1 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,400 Underlying: Common Stock · 16,400 shares Expires 2030-05-20 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on May 21, 2021, provided that the reporting person continues to serve as a director of the issuer through such date. Read SEC document |
| May 20, 2020 Filed May 22, 2020 20:20 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantStock Option (Right to Purchase) · Derivative | 8,095 | $0.00 Strike: $22.05 | $0.00 |
DisclosureSEC source: 0001192482-20-000361 · edgar.xml · derivative · entry 2 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,095 Underlying: Common Stock · 8,095 shares Expires 2030-05-20 F2 · derivative.exercise_date: The option vests and becomes exercisable on May 20, 2021, subject to the director's continued service with the issuer. Read SEC document |
| May 20, 2020 Filed May 22, 2020 20:20 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 4,047 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-20-000361 · edgar.xml · nonDerivative · entry 1 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,007 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 20, 2021, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 23:17 UTC | TETRAPHASE PHARMACEUTICALS INC TTPH · Entity 147285 | GrantStock option (right to buy) · Derivative | 16,500 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001209191-19-036254 · doc4.xml · derivative · entry 1 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2029-06-09 F1 · derivative.exercise_date: Vests in equal quarterly installments over a one-year period measured from the date of grant. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 12:53 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.43 | $0.00 |
DisclosureSEC source: 0001209191-19-035373 · doc4.xml · derivative · entry 1 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-06-05 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on June 6, 2020, provided that the reporting person continues to serve as a director of the issuer through such date. Read SEC document |
| April 25, 2019 Filed Apr 29, 2019 22:42 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantStock Option (Right to Purchase) · Derivative | 9,414 | $0.00 Strike: $14.57 | $0.00 |
DisclosureSEC source: 0001192482-19-000211 · edgar.xml · derivative · entry 2 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,414 Underlying: Common Stock · 9,414 shares Expires 2029-04-25 F2 · derivative.exercise_date: The option vests and becomes exercisable on April 25, 2020, subject to the director's continued service with the issuer. Read SEC document |
| April 25, 2019 Filed Apr 29, 2019 22:42 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 4,707 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000211 · edgar.xml · nonDerivative · entry 1 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,960 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on April 25, 2020, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock. Read SEC document |
| June 19, 2018 Filed Jun 20, 2018 20:25 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $18.80 | $0.00 |
DisclosureSEC source: 0001209191-18-038771 · doc4.xml · derivative · entry 1 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2028-06-18 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on June 19, 2019, provided that the reporting person continues to serve as a director of the issuer through such date. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 20:31 UTC | Protara Therapeutics, Inc. PRTO · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 12,700 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001171843-18-004578 · formfour.xml · derivative · entry 1 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,700 Underlying: Common Stock · 12,700 shares Expires 2028-06-07 F1 · derivative.exercise_date: The options were granted on June 8, 2018 and the shares underlying this option will vest 100% at the earlier of (i) June 8, 2019 and (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 20:12 UTC | TETRAPHASE PHARMACEUTICALS INC TTPH · Entity 147285 | GrantStock option (right to buy) · Derivative | 12,500 | $0.00 Strike: $3.68 | $0.00 |
DisclosureSEC source: 0001209191-18-034652 · doc4.xml · derivative · entry 1 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-05-29 F1 · derivative.exercise_date: Vests in equal quarterly installments over a one-year period measured from the date of grant. Read SEC document |
| May 24, 2018 Filed May 29, 2018 21:05 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantStock Option (Right to Purchase) · Derivative | 4,506 | $0.00 Strike: $24.95 | $0.00 |
DisclosureSEC source: 0001192482-18-000253 · edgar.xml · derivative · entry 2 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,506 Underlying: Common Stock · 4,506 shares Expires 2028-05-24 F2 · derivative.exercise_date: The option vests and becomes exercisable on May 24, 2019, subject to the director's continued service with the issuer. Read SEC document |
| May 24, 2018 Filed May 29, 2018 21:05 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 2,253 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-18-000253 · edgar.xml · nonDerivative · entry 1 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,253 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 24, 2019, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date in shares of the issuer's common stock. Read SEC document |
| November 14, 2017 Filed Nov 14, 2017 22:02 UTC | Protara Therapeutics, Inc. PRTO · Entity 6203 | GrantCommon Stock | 3,812 | $1.89 | $7,200.87 |
DisclosureSEC source: 0001171843-17-007020 · formfour.xml · nonDerivative · entry 3 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,312 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2017. F4 · price: The purchase price of $1.889 is reflective of the weighted average purchase price of all transactions reported on this line. The prices for the transactions reported on this line range from $1.71 to $1.911. The reporting person undertakes to provide Proteon Therapeutics, Inc., any security holder of Proteon Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 13, 2017 Filed Nov 14, 2017 22:02 UTC | Protara Therapeutics, Inc. PRTO · Entity 6203 | GrantCommon Stock | 25,700 | $1.92 | $49,292.60 |
DisclosureSEC source: 0001171843-17-007020 · formfour.xml · nonDerivative · entry 2 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,500 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2017. F3 · price: The purchase price of $1.918 is reflective of the weighted average purchase price of all transactions reported on this line. The prices for the transactions reported on this line range from $1.905 to $1.96. The reporting person undertakes to provide Proteon Therapeutics, Inc., any security holder of Proteon Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 10, 2017 Filed Nov 14, 2017 22:02 UTC | Protara Therapeutics, Inc. PRTO · Entity 6203 | GrantCommon Stock | 23,800 | $1.96 | $46,719.40 |
DisclosureSEC source: 0001171843-17-007020 · formfour.xml · nonDerivative · entry 1 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,800 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2017. F2 · price: The purchase price of $1.963 is reflective of the weighted average purchase price of all transactions reported on this line. The prices for the transactions reported on this line range from $1.91 to $2.01. The reporting person undertakes to provide Proteon Therapeutics, Inc., any security holder of Proteon Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 20, 2017 Filed Jun 21, 2017 20:17 UTC | Protara Therapeutics, Inc. PRTO · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 6,666 | $0.00 Strike: $1.30 | $0.00 |
DisclosureSEC source: 0001171843-17-003745 · formfour.xml · derivative · entry 1 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,666 Underlying: Common Stock, $0.001 par value · 6,666 shares Expires 2027-06-19 F1 · derivative.exercise_date: The options were granted on June 20, 2017 and the shares underlying this option will vest 100% at the earlier of (i) June 20, 2018 and (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 20:38 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $9.18 | $0.00 |
DisclosureSEC source: 0001209191-17-040536 · doc4.xml · derivative · entry 1 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2027-06-14 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on June 15, 2018, provided that the holder continues to serve as a director of the issuer through such date. Read SEC document |
| May 31, 2017 Filed Jun 1, 2017 21:00 UTC | TETRAPHASE PHARMACEUTICALS INC TTPH · Entity 147285 | GrantStock option (right to buy) · Derivative | 12,500 | $0.00 Strike: $6.89 | $0.00 |
DisclosureSEC source: 0001209191-17-036836 · doc4.xml · derivative · entry 1 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2027-05-30 F1 · derivative.exercise_date: Vests in equal quarterly installments over a one-year period measured from the date of grant. Read SEC document |
| May 24, 2017 Filed May 25, 2017 20:42 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantStock Option (Right to Purchase) · Derivative | 19,853 | $0.00 Strike: $9.33 | $0.00 |
DisclosureSEC source: 0001192482-17-000140 · edgar.xml · derivative · entry 1 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,853 Underlying: Common Stock · 19,853 shares Expires 2027-05-24 F1 · derivative.exercise_date: The option vests and becomes exercisable on May 24, 2018, subject to the director's continued service with the issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.